(2-硝基-苯基)-[2]吡啶基酮 | 50678-83-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (2-硝基-苯基)-[2]吡啶基酮
• 英文名称: (2-nitrophenyl)(pyridin-2-yl)methanone
• 英文别名: (2-nitro-phenyl)-[2]pyridyl ketone；(2-Nitro-phenyl)-[2]pyridyl-keton；2-(2-Nitrobenzoyl)-pyridin；2-(2-Nitrobenzoyl)pyridine；(2-nitrophenyl)-pyridin-2-ylmethanone
• CAS: 50678-83-6
• 化学式: C₁₂H₈N₂O₃
• 分子量: 228.207
• InChiKey: RACXVAZCZWTKRU-UHFFFAOYSA-N

物化性质

• 熔点：
  118 °C
• 沸点：
  435.3±25.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-硝基-苯基)-[2]吡啶基酮 在 盐酸 、 tin(ll) chloride 作用下， 生成 2-(2-氨基苯甲酰)吡啶
  参考文献：
  名称：

  508. Cinnolines。第二十四部分。杂环核是Widman-Stoermer合成中的取代基。第一部分。吡啶基和喹啉基核

  摘要：

  DOI：

  10.1039/jr9490002408
• 作为产物：
  描述：

  2-(2,4-二硝基苯甲基)吡啶 在 盐酸 、 potassium permanganate 、 硫化氢 、 氨 、 水 、 连二磷酸 、 sodium nitrite 作用下， 生成 (2-硝基-苯基)-[2]吡啶基酮
  参考文献：
  名称：

  105.一些邻氨基苯吡啶基和喹啉基甲醇

  摘要：

  DOI：

  10.1039/jr9520000589

文献信息

• Cp*Rh^III -Catalyzed Directed Amidation of Aldehydes with Anthranils
  作者：Suvankar Debbarma、Modhu Sudan Maji

  DOI：10.1002/ejoc.201700457

  日期：2017.7.7

  towards construction of amide C–N bonds under mild conditions through rhodium(III) catalysis has been explored. Previous waste-free amidations were generally limited to the condensation of carboxylic acids and amines. In this report, we directly applied amination of the aldehyde C(sp2)–H bond to extend the scope of amidation reactions. The amination shows a wide substrates scope, and several important

  探索了在温和条件下通过铑（III）催化构建酰胺C–N键的方法。先前的无浪费的酰胺化作用通常限于羧酸和胺的缩合。在本报告中，我们直接应用了醛C（sp 2）–H键的胺化反应来扩展酰胺化反应的范围。胺化反应显示出较宽的底物范围，并且在良性反应条件下可耐受几个重要的官能团。合成的酰胺是制备各种生物活性天然产物中存在的苯并恶嗪酮衍生物的重要前体。
• Room Temperature Metal-Catalyzed Oxidative Acylation of Electron-Deficient Heteroarenes with Alkynes, Its Mechanism, and Application Studies
  作者：Shweta Sharma、Mukesh Kumar、Ram A. Vishwakarma、Mahendra K. Verma、Parvinder Pal Singh

  DOI：10.1021/acs.joc.8b01475

  日期：2018.10.19

  room-temperature, regioselective Minisci reaction for the acylation of electron-deficient heteroarenes with alkynes. The method has broad functional group compatibility and gives exclusively monoacylated products in good to excellent yields. The mechanistic pathway was analyzed based on a series of experiments confirming the involvement of a radical pathway. The 18O-labeling experiment suggested that water

  在这里，我们报告原始的一步式，简单的，室温，区域选择性Minisci反应，用于炔烃与缺电子的杂芳烃的酰化反应。该方法具有广泛的官能团相容性，并以良好至极佳的收率提供仅单酰化的产物。基于一系列实验证实了自由基途径的参与，对机械途径进行了分析。的18 O型标记实验表明，水是氧在酰化产物的源极，和头部空间GC-MS实验表明通过释放发生的C-C切割为CO 2。
• Aerobic Oxidation of Pd^II to Pd^IV by Active Radical Reactants: Direct C–H Nitration and Acylation of Arenes via Oxygenation Process with Molecular Oxygen
  作者：Yu-Feng Liang、Xinyao Li、Xiaoyang Wang、Yuepeng Yan、Peng Feng、Ning Jiao

  DOI：10.1021/cs502126n

  日期：2015.3.6

  oxidative C–H nitration and acylation of arenes with simple and readily available tert-butyl nitrite (TBN) and toluene as the radical precursors has been developed. Molecular oxygen is employed as the terminal oxidant and oxygen source to initiate the active radical reactants. Many different directing groups such as pyridine, pyrimidine, pyrazole, pyridol, pyridylketone, oxime, and azo groups can be employed

  已经开发了钯催化的好氧氧化C–H硝化和芳烃与简单易用的亚硝酸叔丁酯（TBN）和甲苯作为自由基前体的酰化反应。分子氧被用作末端氧化剂和氧源以引发活性自由基反应物。在这些新颖的转化中可以使用许多不同的导向基团，例如吡啶，嘧啶，吡唑，吡啶醇，吡啶基酮，肟和偶氮基团。通过自由基过程的Pd II / Pd IV催化循环是这些氧化的CH–H硝化和酰化反应的最可能途径。
• CCLXIII.—2-o-Aminobenzylpyridine
  作者：Robert Hugh Wilson

  DOI：10.1039/jr9310001936

  日期：——
• [EN] 2-PHENYLAMINO-4- 5-PYRAZOLYLAMINO -PYRAMIDINE DERIVATIVES AS KINASE INHIBITORS, IN PARTICULAR, SRC KINASE INHIBITORS<br/>[FR] DERIVES DE LA 2-PHENYLAMINO-4- (5-PYRAZOLYLAMINO) -PYRAMIDINE, INHIBITEURS DE KINASES ET EN PARTICULIER DE LA KINASE SRC
  申请人：BAYER AG

  公开号：WO2003026664A1

  公开（公告）日：2003-04-03

  The invention provides novel substituted 2,4-diaminopyrimidine compounds (I). In formula (I), the variables are as follows. Y1 represents H or C 1-4 alkyl. Y2 represents CF3, C1-6 alkyl; C3-6 cycloalkyl; or phenyl optionally substituted with halogen, C1-4 alkyl, or C1-4 alkoxy. The subscript n is 0, 1, or 2. X represents halogen or C1-4 alkyl, p is 0, 1, or 2. Z represents halogen, C1-4 alkyl, or C1-4 alkoxy; and q is 0, 1, or 2. L represents a chemical bond; C1-4 alkylene; O; O(C1-4 alkylene); CH(C1-6 alkoxy); S(O)0-2; S(O)0-2(C1-4 alkylene); (C1-4 alkylene)S(O)0-2; NH(C1-4 alkylene); C(O); or C(O)-(C1-4 alkylene). D represents pyridinyl; imidazolyl; thiazolyl; pyrrolyl; thienyl; pyrazolyl; furyl; thiadiazolyl; oxazolyl; or benzimidazolyl. The pyridinyl and benzimidazolyl groups D each may be optionally substituted by up to three substituents independently selected from C1-4 alkyl, OH, C1-4 alkoxy, CN, NR1R2, C(O)NR1R2, halogen, and CO2(C1-6 alkyl), in which R1 and R2 are independently selected from H, C1-4 alkyl, and C3-6 cycloalkyl. Alternatively, R1 and R2 may be joined to form a 5-6 membered saturated heterocycle (II) in which Q represents O, S(O)0-2, N-Y1, or C(Y1)2, pharmaceutical compositions containing them, a method of making them, and methods of using them for treatment of cell proliferative diseases such as cancer, and non-malignant cell proliferative diseases, as well as osteoporosis and inflammatory diseases.